Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV001288573 | SCV001475788 | uncertain significance | not provided | 2020-02-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002322179 | SCV002609659 | uncertain significance | Cardiovascular phenotype | 2019-08-20 | criteria provided, single submitter | clinical testing | The p.E10661K variant (also known as c.31981G>A), located in coding exon 127 of the TTN gene, results from a G to A substitution at nucleotide position 31981. The glutamic acid at codon 10661 is replaced by lysine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |